Bristol Expands Immunotherapy Footprint With Anti-PD-1

In a Phase I trial reported at ASCO, BMS’ new immunotherapeutic antibody BMS-936558 had impressive results against melanoma, renal cell cancer and non-small cell lung cancer, including the intractable squamous cell variety. The company is already testing it in combination with Yervoy to “move melanoma treatment to new heights.”